The American Society of Hematology sent a couple of updates today. All a tad specialised, but all useful snippets. I particularly found the bit about ABO mismatched platelets to be interesting. Considering there aren’t (supposed to be) A or B antigens on platelets, how does that work?
Here are the highlights in bleeding disorders:
ASH Clinical News is following the 26th Annual Congress of the European Hematology Association to report on the latest advances in hematologic malignancies. Here’s a look at some of the highlights:
Head-to-Head Trial Confirms Acalabrutinib’s Noninferiority to Ibrutinib in CLL
For the treatment of patients with CLL, acalabrutinib is noninferior to ibrutinib in terms of progression-free survival and was associated with lower incidence of common adverse events, such as atrial fibrillation.
B-Cell Depletion Linked to Prolonged COVID-19 in Lymphoma
A study of patients with B-cell non-Hodgkin lymphoma hospitalized for COVID-19 has found that these patients had a higher incidence of prolonged evolution of the SARS-CoV-2 infection.
PDE9 Inhibitor Shows Promise as Monotherapy and With Hydroxyurea in Sickle Cell Disease
Daily dosing of the oral phosphodiesterase type 9 inhibitor IMR-687, at doses up to 200 mg, was safe and well-tolerated as a monotherapy or in combination with hydroxyurea in patients with sickle cell disease.